NCT03048279View on ClinicalTrials.gov

Registry for Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2

Active, not recruitingOBSERVATIONAL
Enrollment

1,500

Participants

Timeline

Start Date

September 5, 2001

Primary Completion Date

September 1, 2026

Study Completion Date

September 1, 2026

Conditions
Multiple Endocrine Neoplasia Syndromes
Interventions
BEHAVIORAL

Questionnaires

"Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2 Group: Participants interviewed by phone and/or mail to obtain medical history specific to their diagnosis of either MEN1 or MEN2.~Close Relatives of Registered MDACC MEN Patients Group: Participants asked to complete a health and family history questionnaire. This questionnaire process may be completed by phone or mail."

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT03048279 - Registry for Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2 | Biotech Hunter | Biotech Hunter